The difficult patient: Drug interaction and the influence of concomitant diseases on the treatment of hypothyroidism;O paciente difícil: Interação entre drogas e influência de doenças concomitantes no tratamento do hipotiroidismo

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 54, Issue 5, 2010, Pages 435-442

  Ward, Laura S ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Absor o; Absorption; Ades o; Bioequivalence; Bioequival ncia; Compliance; Comportamento; H bitos alimentares; Medication taking behavior; Nutritional habits

Indexed keywords

EID: 77956791809     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302010000500002     Document Type: Review

References (58)

1. Saravanan P, Chau WF, Roberts N, Vedhara K, Greenwood R, Dayan CM. Psychological well-being in patients on 'adequate' doses of l-thyroxine: results of a large, controlled community-based questionnaire study. Clin Endocrinol. 2002;57(5):577-85.
2. Dayan CM, Panicker V. Novel insights into thyroid hormones from the study of common genetic variation. Nat Rev Endocrinol. 2009;5(4):211-8.
3. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens. 2006;19(11):1190-6.
4. Friedman O, McAlister FA, Yun L, Campbell NR, Tu K; Canadian Hypertension Education Program Outcomes Research Taskforce. Antihypertensive drug persistence and compliance among newly treated elderly hypertensives in Ontario. Am J Med. 2010;123(2):173-81.
5. Bagattoli RM, Vaisman M, Lima JS, Ward LS. Estudo de adesão ao tratamento do hipotiroidismo. Arq Bras Endocrinol Metab. 2000;44(6):483-7.
6. Morris JC. How do you approach the problem of TSH elevation in a patient on high-dose thyroid hormone replacement? Clin Endocrinol. 2009;70(5):671-3.
7. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, et al. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab. 2005;90(1):124-7.
8. Asvold BO, Bjøro T, Vatten LJ. Association of serum TSH with high body mass differs between smokers and never-smokers. J Clin Endocrinol Metab. 2009;94(12):5023-7.
9. Weiss RE, Brown RL. Doctor. Could it be my thyroid? Arch Intern Med. 2008;168(6):568-9.
10. Kok P, Roelfsema F, Langendonk JG, Frölich M, Burggraaf J, Meinders AE, et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. J Clin Endocrinol Metab. 2005;90(8):4659-63.
11. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. J Clin Endocrinol Metab. 2006;91(8):3088-91.
12. Onur S, Haas V, Bosy-Westphal A, Hauer M, Paul T, Nutzinger D, Klein H, et al. L-tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. Eur J Endocrinol. 2005;152(2):179-84.
13. Knudsen N, Bülow I, Laurberg P, Ovesen L, Perrild H, Jørgensen T. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab. 2005;90(7):4019-24.
14. Jonklaas J. Sex and age differences in levothyroxine dosage requirement. Endocr Pract. 2010;16(1):71-9.
15. Sawin CT, Herman T, Molitch ME, London MH, Kramer SM. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med. 1983;75(2):206-9.
16. American Thyroid Association; Endocrine Society; American Association of Clinical Endocrinologists. Joint statement on the U.S. Food and Drug Administration's decision regarding bioequivalence of levothyroxine sodium. Thyroid. 2004;14(7):486.
17. Hennessey JV, Malabanan AO, Haugen BR, Levy EG. Adverse Event Reporting in Patients Treated with Levothyroxine: Results of the Pharmacovigilance Task Force Survey of the American Thyroid Association, American Association of Clinical Endocrinologists and The Endocrine Society. Endocr Pract. 2010 Feb 11:1-41. [Epub ahead of print]
18. Read DG, Hays MT, Hershman JM. Absorption of oral thyroxine in hypothyroid and normal man. J Clin Endocrinol Metab. 1970;30(6):798-9.
19. Benvenga S, Bartolone L, Squadrito S, Lo Giudice F, Trimarchi F. Delayed intestinal absorption of levothyroxine. Thyroid. 1995;5(4):249-53.
20. Read DG, Hays MT, Hershman JM. Absorption of oral thyroxine in hypothyroid and normal man. J Clin Endocrinol Metab. 1970;30(6):798-9.
21. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med. 2006;354(17):1787-95.
22. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 1977;26(1):1-8.
23. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol. 2003;65:103-31.
24. Hennemann G, Docter R, Friesema EC, de Jong M, Krenning EP, Visser TJ. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev. 2001;22:451-76.
25. Centanni M, Robbins J. Role of sodium in thyroid hormone uptake by rat skeletal muscle. J Clin Invest. 1987;80:1068-72.
26. Annibale B, Marignani M, Azzoni C, D'Ambra G, Caruana P, D'Adda T, et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter. 1997;2:57-64.
27. Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med. 1999;159:1726-30.
28. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet. 1995;345:1525-8.
29. Sachs G, Shin JM, Munson K, Vagin O, Lambrecht N, Scott DR, et al. Review: the control of gastric acid and Helicobacter pylori eradication. Aliment Pharmacol Ther. 2000;14:1383-401.
30. Yao X, Forte JG. Cell biology of acid secretion by the parietal cell. Annu Rev Physiol. 2003;65:103-31.
31. Lahner E, Annibale B, Delle Fave G. Systematic review: Helicobacter pylori infection and impaired drug absorption. Aliment Pharmacol Ther. 2009;29(4):379-86.
32. Ananthakrishnan S, Braverman LE, Levin RM, Magnani B, Pearce EN. The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid. 2008;18(5):493-8.
33. Singh N, Weisler SL, Hershman JM. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid. 2001;11(10):967-71.
34. Collin P, Kaukinen K, Välimäki M, Salmi J. Endocrinological disorders and celiac disease. Endocr Rev. 2002;23:464-83.
35. Boelaert K, Newby PR, Simmonds MJ, Holder RL, Carr-Smith JD, Heward JM, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. Am J Med. 2010;123(2):183.e1-9.
36. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. J Am Med Assoc. 2004;291:228-38.
37. McDermott JH, Coss A, Walsh CH. Celiac disease presenting as resistant hypothyroidism. Thyroid. 2005;15(4):386-8.
38. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11:41-50.
39. Seppel T, Rose F, Schlaghecke R. Chronic intestinal giardiasis with isolated levothyroxine malabsorption as reason for severe hypothyroidism - implications for localization of thyroid hormone absorption in the gut. Exp Clin Endocrinol Diabetes. 1996;104(2):180-2.
40. Muñoz-Torres M, Varsavsky M, Alonso G. Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid. 2006;16(11):1171-3.
41. Pantos C, Mourouzis I, Xinaris C, Cokkinos DV. Thyroid hormone and myocardial ischaemia. J Steroid Biochem Mol Biol. 2008;109(3-5):314-22.
42. Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med. 1996;101(5):461-7.
43. Goarin JP, Cohen S, Riou B, Jacquens Y, Guesde R, Le Bret F, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg. 1996;83(1):41-7.
44. Cooper DK, Novitzky D, Wicomb WN, Basker M, Rosendale JD, Myron Kauffman H. A review of studies relating to thyroid hormone therapy in brain-dead organ donors. Front Biosci. 2009;14:3750-70.
45. Mullis-Jansson SL, Argenziano M, Corwin S, Homma S, Weinberg AD, Williams M, et al. A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery. J Thorac Cardiovasc Surg. 1999;117(6):1128-34.
46. Novitzky D, Cooper DK, Swanepoel A. Inotropic effect of triiodothyronine (T3) in low cardiac output following cardioplegic arrest and cardiopulmonary bypass: an initial experience in patients undergoing open heart surgery. Eur J Cardiothorac Surg. 1989;3(2):140-5.
47. Henderson KK, Danzi S, Paul JT, Leya G, Klein I, Samarel AM. Physiological replacement of T3 improves left ventricular function in an animal model of myocardial infarction-induced congestive heart failure. Circ Heart Fail. 2009;2(3):243-52.
48. Brent GA, Hershman JM. Thyroxine therapy in patients with severe nonthyroidal illnesses and low serum thyroxine concentration. J Clin Endocrinol Metab. 1986;63(1):1-8.
49. Sandek A, Rauchhaus M, Anker SD, von Haehling S. The emerging role of the gut in chronic heart failure. Curr Opin Clin Nutr Metab Care. 2008;11(5):632-9.
50. Benvenga S, Bartolone L, Pappalardo MA, Russo A, Lapa D, Giorgianni G, et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008;18(3):293-301.
51. Chiu AC, Sherman SI. Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid. 1998;8(8):667-71.
52. Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol. 2005;60(3):337-41.
53. Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735-51.
54. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6(1):34-41.
55. Silva JR, Guariento ME, Fernandes GA, Maciel RMB, Ward LS. Impact of long-term administration of amiodarone on the thyroid function of Chagas' disease patients. Thyroid. 2004;14(5):373-9.
56. Cappelli C, Rotondi M, Pirola I, Agosti B, Gandossi E, Valentini U, et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care. 2009;32(9):1589-90.
57. Patrick L. Thyroid disruption: mechanism and clinical implications in human health. Altern Med Rev. 2009;14(4):326-46.
58. Uzma N, Salar BM, Kumar BS, Aziz N, David MA, Reddy VD. Impact of organic solvents and environmental pollutants on the physiological function in petrol filling workers. Int J Environ Res Public Health. 2008;5(3):139-46.